We are live on ! Find out more
LBPS

4D Pharma PLC

Delisted

LBPS was delisted on the 24th of June, 2022.

1 hedge funds and large institutions have $0 invested in 4D Pharma PLC in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% less funds holding

Funds holding: 81 (-7)

100% less capital invested

Capital invested by funds: $430K → $0 (-$430K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
1
Holders Change
-7
Holders Change %
-87.5%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RL
1
Ruffer LLP
United Kingdom
-$320K -195,954 Closed
Citadel Advisors
2
Citadel Advisors
Florida
-$46K -28,166 Closed
Capstone Investment Advisors
3
Capstone Investment Advisors
New York
-$25K -15,200 Closed
WAM
4
Wolverine Asset Management
Illinois
-$13K -8,055 Closed
Osaic Holdings
5
Osaic Holdings
Arizona
-$8K -4,799 Closed
Morgan Stanley
6
Morgan Stanley
New York
-$7K -4,360 Closed
CS
7
Credit Suisse
Switzerland
-$3K -1,638 Closed

LBPS Hedge Fund Activity: Q3 2022 in Review

1 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q3 2022, worth a combined $0 — down 100% from $430K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of LBPS and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Ruffer LLP, exiting entirely with an estimated $320K sold.

  • 1 institutional investor held 4D Pharma PLC (LBPS) as of Q3 2022, down from 8 in Q2 2022.
  • Funds reported $0 of 4D Pharma PLC stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new 4D Pharma PLC positions in Q3 2022 and 7 closed out, a net change of -7 holders.
  • The largest 4D Pharma PLC seller in Q3 2022 was Ruffer LLP, an estimated $320K sold.

Based on aggregated 13F filings for Q3 2022.